3. 脊髄性筋萎縮症 Spinal muscular atrophy Clinical trials / Disease details
臨床試験数 : 237 / 薬物数 : 123 - (DrugBank : 29) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 75
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05337553 (ClinicalTrials.gov) | July 6, 2022 | 14/4/2022 | A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy | A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Ambulatory and Non-Ambulatory Participants With Spinal Muscular Atrophy With Open-Label Extension | Spinal Muscular Atrophy;Neuromuscular Diseases;SMA | Drug: taldefgrobep alfa;Drug: Placebo | Biohaven Pharmaceuticals, Inc. | NULL | Recruiting | 4 Years | 21 Years | All | 225 | Phase 3 | United States;Belgium;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom |